Am 08. und 09.10.2024 findet an der Technischen Universität Berlin unter dem Namen „Our UNIverse: Empowered to speak up“ eine deutschlandweite Tagung zum Thema Machtmissbrauch an Hochschulen statt. Ziel der Tagung ist es nicht nur, das Bewusstsein für das Thema zu schärfen, sondern auch die aktuelle Situation an Universitäten zu analysieren. Das Tagungsprogramm kann hier (https://www.tu.berlin/go266200/) abgerufen werden. Einige Highlights sind:• Key Note: Machtmissbrauch in der Wissenschaft mit Prof. Dr. Jutta Stahl, Professorin für differentielle Psychologie und psychologische Diagnostik, Universität zu Köln• Key Note: Politische Stellschrauben im Kampf gegen Machtmissbrauch mit Carolin Wagner, SPD MdB• Podiumsdiskussion: Wie kann man die Mauer des Schweigens brechen?• Workshops & Vorträge: Machtmissbrauch verstehen, Best Practices, Maßnahmen gegen Machtmissbrauch entwickeln.

Ein neues, leistungsfähiges Analysetool ermöglicht einen genaueren Einblick in die Art und Weise, wie Tumorzellen ihre Form verändern und so aggressiver und unbehandelbarer werden. Dies zeigt eine Studie von Forschern des Weill Cornell Medicine und des  New York Genome Center . Eine Tumorzelle verändert ihre Form, indem sie ihren Zelltyp oder Zustand ändert, wodurch sich ihr grundlegendes Aktivitätsmuster und möglicherweise sogar ihr Aussehen verändert. Diese Veränderlichkeit oder „Plastizität“ ist ein Merkmal von Krebs, das zu unterschiedlichen Tumorzellpopulationen und schließlich zur Entstehung von Zelltypen führt, die eine Behandlungsresistenz und Metastasierung ermöglichen. Mit dem neuen Werkzeug, das am 24. September in einem  Artikel  in Nature Genetics beschrieben wurde, lässt sich diese Plastizität in Tumorzellproben quantifizieren. Die Forscher demonstrierten dies anhand von Analysen von Tumorproben aus Tiermodellen und menschlichen Patienten und identifizierten beispielsweise einen wichtigen Übergangszustand der Zelle beim Glioblastom, der häufigsten Form… 

Anixa Biosciences, Inc. („Anixa“ or the „Company“) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its strategic plan for a Phase 2 study for its breast cancer vaccine. The Phase 1 trial is being conducted at Cleveland Clinic, funded by a grant from the U.S. Department of Defense. The proposed Phase 2 trial will evaluate the efficacy of the vaccine administered in the neoadjuvant (before surgery) setting, in combination with chemotherapy and Keytruda (pembrolizumab). The goal of neoadjuvant therapy is to reduce tumor burden and to prevent tumor recurrence with the intent to improve survival. This clinical trial approach allows Anixa to enroll a broader range of patients, encompassing multiple types of breast cancer.

B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Introcan Safety® 2 Deep Access IV Catheter, the newest addition to the Introcan Safety 2 IV Catheter portfolio. The Introcan Safety 2 Deep Access IV Catheter merges the trusted technologies of the original Introcan Safety 2 Multi-Access and Introcan Safety Deep Access Catheters, offering clinicians an advanced solution that combines the strengths of both devices. This innovative catheter provides fully automatic passive safety needlestick protection and multi-access blood control in longer lengths and is designed to access deeper veins in patients with difficult vascular access and to achieve longer dwell times.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) („NeuroSense“), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the issuance of a pivotal patent by the United States Patent and Trademark Office (USPTO). The newly granted patent, entitled „Compositions comprising Ciprofloxacin and Celecoxib“ (US Patent No. US 12,097,185), relates to the novel formulation of PrimeC, NeuroSense’s leading drug candidate for the treatment of Amyotrophic Lateral Sclerosis (ALS). This patent is expected to extend PrimeC’s patent  protection by an additional four years, until 2042. PrimeC is composed of ciprofloxacin and celecoxib, two FDA-approved compounds in unique doses, formulated in a technology of slow release to synchronize their pharmacokinetic (PK) profiles and enhance their therapeutic synergy. This innovative approach is designed to optimize the treatment efficacy in slowing ALS progression. The patent grant follows NeuroSense’s recent clinical findings, where PrimeC… 

Yale School of Medicine (YSM) developmental biologist Dr. Valentina Greco has been named one of Cell Press’s „50 Scientists that Inspire.“ Cell Press curated the list as part of its 50th anniversary celebration. Greco is the Carolyn Walch Slayman Professor of Genetics and professor of cell biology and dermatology at YSM, a member of Yale Cancer Center and the Yale Stem Cell Center, and co-chair of the Status of Women in Medicine. She is president-elect of the International Society for Stem Cell Research.

Our immune system spans two worlds—innate and adaptive. Innate immune cells are like troops at the gate ready to hold off invaders and raise the body’s alarms. Adaptive immune cells are specialists that take longer to respond but can fight off foes in a more targeted manner. Curiously, there are also immune cells that exist between worlds. Important among these cellular combatants are innate-like T cells. Their hybrid-like nature makes them promising candidates for developing new kinds of immunotherapies against diseases such as cancer. The problem is that scientists still don’t know much about how this unique type of T cell functions and develops in humans. Cold Spring Harbor Laboratory (CSHL) Assistant Professor Hannah Meyer and her collaborator at the University of Colorado Anschutz, Professor Laurent Gapin, set out to determine just that. „Studying the development of the immune system… 

Fzata, Inc. is pleased to announce a five-year UG3/UH3 non-dilutive grant (UG3NS135350) of up to $7 million, plus in-kind contributions, awarded by the NIH National Institute of Neurological Disorders and Stroke (NINDS). Grant participants include Fzata and the University of Maryland, Baltimore (UMB). The grant supports development of BioPYM™ drug candidate FZ006 as a safe and effective oral treatment for chronic visceral pain associated with inflammatory bowel syndrome (IBS). Work under the grant will include IND-enabling studies, GLP toxicology, cGMP manufacturing, phase 1 trial design, IND submission, and Phase 1a clinical trial.